39.12

1.19% 0.43

Exelixis Inc (EXEL)

Overview News Price History Option Chain Financials Why EXEL Down? Discussions Forecast

Exelixis Inc stock is traded at $39.12, with a volume of 1.56M. It is up +1.19% in the last 24 hours and up +19.07% over the past month. Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Previous Close:

$38.69

Open:

$38.8

24h Volume:

1.56M

Relative Volume:

0.69

Market Cap:

$10.83B

Revenue:

$2.08B

Net Income/Loss:

$466.92M

P/E Ratio:

25.08

EPS:

1.56

Net Cash Flow:

$404.94M

1W Performance:

+5.44%

1M Performance:

+19.07%

6M Performance:

+51.57%

1Y Performance:

+76.03%

1-Day Range:

$38.04

$39.30

1-Week Range:

$36.16

$39.30

52-Week Range:

$20.14

$39.30

Exelixis Inc Stock (EXEL) Company Profile

Name

Exelixis Inc

Sector

Healthcare (1188)

Industry

Biotechnology (679)

Phone

(650) 837-7000

Address

1851 HARBOR BAY PARKWAY, ALAMEDA, CA

Employee

1,147

Twitter

@exelixisinc

Next Earnings Date

2025-02-11

Latest SEC Filings

EXEL's Discussions on Twitter

Compare EXEL with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EXEL Exelixis Inc	39.12	10.83B	2.08B	466.92M	404.94M	1.56
VRTX Vertex Pharmaceuticals Inc	488.58	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	688.84	75.07B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	634.75	37.96B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	242.40	31.79B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	112.82	27.34B	3.30B	-501.07M	1.03B	-2.1146

Exelixis Inc Stock (EXEL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-24-25	Downgrade	Wells Fargo	Overweight → Equal Weight
Jan-27-25	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jan-24-25	Downgrade	Oppenheimer	Outperform → Perform
Dec-20-24	Downgrade	BMO Capital Markets	Outperform → Market Perform
Dec-17-24	Downgrade	BofA Securities	Buy → Neutral
Oct-16-24	Reiterated	RBC Capital Mkts	Outperform
Sep-19-24	Initiated	UBS	Neutral
Apr-11-24	Downgrade	Barclays	Overweight → Equal Weight
Dec-19-23	Initiated	BTIG Research	Buy
Dec-15-23	Initiated	Citigroup	Buy
Sep-26-23	Initiated	H.C. Wainwright	Buy
Aug-22-23	Reiterated	Oppenheimer	Outperform
Aug-08-23	Initiated	SVB Securities	Market Perform
Jul-11-23	Resumed	Morgan Stanley	Equal-Weight
May-10-23	Resumed	Piper Sandler	Overweight
Mar-09-23	Initiated	Wells Fargo	Overweight
Jan-26-23	Initiated	Credit Suisse	Outperform
Oct-18-22	Initiated	JMP Securities	Mkt Outperform
Jun-24-22	Initiated	BMO Capital Markets	Outperform
Nov-19-21	Initiated	Piper Sandler	Overweight
Nov-03-21	Resumed	Jefferies	Buy
Oct-07-21	Initiated	Jefferies	Buy
Aug-06-21	Reiterated	H.C. Wainwright	Buy
Jun-15-21	Initiated	H.C. Wainwright	Buy
May-18-21	Resumed	Goldman	Sell
Mar-31-21	Initiated	Credit Suisse	Outperform
Mar-12-21	Initiated	Wolfe Research	Outperform
Mar-04-20	Initiated	Barclays	Overweight
Jan-13-20	Initiated	SunTrust	Buy
Nov-13-19	Initiated	BofA/Merrill	Buy
Mar-18-19	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Sep-17-18	Initiated	Goldman	Neutral
Sep-10-18	Initiated	Morgan Stanley	Underweight
May-11-18	Reiterated	Needham	Buy
Oct-17-17	Reiterated	Needham	Buy
Oct-17-17	Reiterated	RBC Capital Mkts	Outperform
Oct-16-17	Reiterated	SunTrust	Buy
Sep-22-17	Downgrade	Leerink Partners	Outperform → Mkt Perform
Sep-15-17	Initiated	RBC Capital Mkts	Outperform
Sep-12-17	Reiterated	Needham	Buy
Jul-14-17	Initiated	SunTrust	Buy
Mar-31-17	Initiated	Needham	Buy
Mar-16-17	Initiated	Oppenheimer	Perform
Feb-28-17	Downgrade	Stifel	Buy → Hold
Nov-03-16	Initiated	Deutsche Bank	Buy
Oct-10-16	Upgrade	Piper Jaffray	Neutral → Overweight
Sep-15-16	Reiterated	Stifel	Buy

View All

Exelixis Inc Stock (EXEL) Latest News

Mar 01, 2025

Is Exelixis, Inc. (EXEL) The Best Immunology Stock To Buy Now? - Insider Monkey

Mar 01, 2025

Feb 28, 2025

10 Best Immunology Stocks To Buy Now - Insider Monkey

Feb 28, 2025

Exelixis director Jack Wyszomierski sells $331,430 in stock By Investing.com - Investing.com Canada

Feb 28, 2025

Exelixis director Jack Wyszomierski sells $331,430 in stock - Investing.com India

Feb 28, 2025

Exelixis director Julie Smith sells $2.8 million in stock - Investing.com

Feb 28, 2025

Exelixis Directors Execute Significant Stock Transactions - TradingView

Feb 28, 2025

BioInvent announces achievement of a research milestone event in its collaboration with Exelixis triggering a USD 1 million milestone payment - ACCESS Newswire

Feb 28, 2025

Exelixis focuses on future growth despite COSMIC-313 trial challenges - Yahoo Finance

Feb 28, 2025

Feb 27, 2025

Exelixis, Inc. to Host Earnings Call - ACCESS Newswire

Feb 27, 2025

Exelixis CFO Christopher Senner sells $1.06 million in stock By Investing.com - Investing.com South Africa

Feb 27, 2025

Exelixis CSO Aftab Dana sells shares worth $991,772 By Investing.com - Investing.com South Africa

Feb 27, 2025

When (EXEL) Moves Investors should Listen - Stock Traders Daily

Feb 27, 2025

Exelixis EVP Haley Patrick sells $1.95 million in company stock By Investing.com - Investing.com South Africa

Feb 27, 2025

Exelixis Stock: Executives Sell as Shares Near Peak - sharewise

Feb 27, 2025

Feb 26, 2025

Exelixis director Oliver Bob sells $694,600 in stock By Investing.com - Investing.com South Africa

Feb 26, 2025

Exelixis CFO Christopher Senner sells $1.06 million in stock - Investing.com India

Feb 26, 2025

Exelixis director Oliver Bob sells $694,600 in stock - Investing.com India

Feb 26, 2025

Exelixis Executives and Director Sell Shares - TradingView

Feb 26, 2025

Exelixis stock hits 52-week high at $37.63 amid robust growth By Investing.com - Investing.com South Africa

Feb 26, 2025

Exelixis stock hits 52-week high at $37.63 amid robust growth - Investing.com India

Feb 26, 2025

Zacks.com featured highlights Gilead Sciences, Exelixis, Synchrony Financial and Molson Coors - Yahoo Finance

Feb 26, 2025

Feb 25, 2025

Exelixis to Webcast Fireside Chats at Upcoming Investor Conferences in March - Business Wire

Feb 25, 2025

Feb 24, 2025

This Conagra Brands Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday - Benzinga

Feb 24, 2025

Wells Fargo Downgrades Exelixis to Equalweight From Overweight, Price Target is $36 - Marketscreener.com

Feb 24, 2025

Feb 23, 2025